EXECUTIVE INTERVIEWS

How Bayer Relieved My Innovation Neurosis

Among her many positive attributes, Dr. Monika Lessl is a good sport. I know because she graciously accepted to enter – at least for the duration of our interview – my neurosis regarding the word “innovation.”

More From Executive Interviews

THE CURRENT ISSUE

  • Rx Industry Fighting Off New Salvos To Extract Medicare Savings
    Rx Industry Fighting Off New Salvos To Extract Medicare Savings

    When the King v. Burwell verdict upholding the Obamacare subsidies was announced, Republicans in Congress breathed a collective sigh of relief. Yes, most of them thought the law was unconstitutional, and a clear reading of the statute that subsidies could only flow to an exchange “established by a State” caused flummoxed consternation. But they had dodged the bullet of what to do with the 7 million individuals receiving subsidies through the federal exchange who were about to lose their coverage.

  • Are We Truly Investing To Meet The World’s Unmet Medical Need?
    Are We Truly Investing To Meet The World’s Unmet Medical Need?

    A recent biopharmaceutical industry analysis by David Thomas and Chad Wessel (Emerging Therapeutic Company Investment and Deal Trends, June 2015) reveals that for the past decade oncology garners more investment than any other disease.

  • 7 Steps For Boosting Your Influence
    7 Steps For Boosting Your Influence

    Today’s organizations are filled with great complexity, undergo rapid change, and have a wide array of workplace cultures and team dynamics. Leaders are expected to influence many people in order to create effective change and deliver better results, all while inspiring and empowering others. Influential leaders are those who can garner help from enough people throughout the organization to achieve or exceed shared goals.

  • Can Nano Bring Us Back From Personalized To Mass Medicine?
    Can Nano Bring Us Back From Personalized To Mass Medicine?

    How big can a singular change in perspective be? As big as a Copernican Revolution, you might say. Or more precisely, perhaps, how small can it be? If it’s the fundamental change that creates a metatheory moving biology to physics, it can be as small as building particles — or deconstructing them — atom-by-atom to bring new drugs to mankind. This is the big and small of nanomedicine (nano).

  • Ask The Board: What Is The Greatest Insight Gained From Attending The 2015 ISPE/FDA Quality Week?
    Ask The Board: What Is The Greatest Insight Gained From Attending The 2015 ISPE/FDA Quality Week?

    In discussions with industry and FDA colleagues, it is clear that understanding supply chain risks is the key to understanding risk of drug shortages. Over the past 10-15 years, the pharma industry has done an excellent job of reducing supply chain costs. However, we may have pushed our focus on efficient supply chains too far, contributing to the increase in quality issues and/or drug shortages in this same period.

  • Why Is Takeda Focusing On Vaccines?
    Why Is Takeda Focusing On Vaccines?

    Succeeding in the vaccines business is not easy. Low margins and manufacturing challenges make it a difficult business for any pharma company. In fact, two large manufacturers, Baxter and Novartis, recently pulled the plug on their vaccine efforts. Four of the remaining sponsor companies, GSK, Merck, Pfizer, and Sanofi Pasteur, are formidable competitors. Despite the challenges that exist, Takeda decided in 2012 to enter this global market, building upon its 70-year history of Japanese vaccine business, with plans to be the world leader by the year 2020.

  • Building A Narrative: Develop Emotional Connections To Raise Capital
    Building A Narrative: Develop Emotional Connections To Raise Capital

    For 55 years, comedian Jerry Lewis hosted Labor Day Muscular Dystrophy Telethons featuring “Jerry’s Kids,” the poster children who made muscular dystrophy real for millions of Americans. By creating an emotional connection with the audience, those telethons raised more than $2 billion.

More Magazine Articles....

FROM THE CUTTING ROOM FLOOR

  • Celgene's M&A Dealer - “The Best Career Decision I Ever Made.”

    For George Golumbeski, the key to becoming good at BD is learning by doing. “I was once asked, ‘What books can one read to learn about negotiations?’” he says. “Forget it. You’ve got to get in there. Hopefully you have somebody who can show you the ropes. And, you are probably going to mess up a few times.” 

  • How Does Being A Scientist Help With Biopharmaceutical Business Development?

    Celgene’s SVP of business development, George Golumbeski, completed his undergraduate degree in biology, a Ph.D. in genetics, and a post doc in molecular biology. So what makes him qualified to run the business development unit for one of the hottest biopharmaceutical companies?

  • Want To Know What Deal Celgene’s George Golumbeski Is Most Proud Of?

    George Golumbeski, Celgene’s SVP of business development, has been listed as one of the most influential folks in all of biotech, the result of the company’s consistent deal-making success, which is his primary role. When I asked him if he had a deal he was most proud of, he replied...

More...

 UPCOMING TRAINING COURSES

Medical Device Complaint Handling and MDR Reporting

August 11, 2015
1pm-2:30pm EDT, Online Training

Monitoring Electronic Health Records (EHRs): Frequently Asked Questions

September 9, 2015
1pm-2:30pm EDT, Online Training

Root Cause Analysis for GCP – A Risk Action Plan Guide

September 22, 2015
1pm-3pm EDT, Online Training

CRO Oversight: Risk Assessment & Action Planning

October 6, 2015
1pm-2:30pm EDT, Online Training
More Upcoming Courses

VIEW THE DIGITAL EDITION

July 2015

 

2015 CRO LEADERSHIP AWARDS - SUPPLEMENT

2015 CRO Leadership Awards

 

 UPCOMING EVENTS

New Pharma Compliant Google Ad Formats – Implementation Tips For Success

August 4, 2015
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!

Project Management: Best Practices for Validation & Regulatory Projects

August 5, 2015
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!

Medical Device Complaint Handling and MDR Reporting

August 11, 2015
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!

Cloud Computing In A GxP Environment: Three Key Success Factors

August 13, 2015
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!

PharmaForce

August 25 - 27, 2015
Pentagon City, VA
See All Events